Residual Tumor Diameter Predicts Progression After Primary Debulking Surgery of Ovarian Clear Cell Carcinoma (OCCC): Clinicopathologic Study of Stage II-IV OCCC Patients from a Single Institution

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Kim SI, Lee JW, Lee M, et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol Oncol. 2018;148(2):375–382. doi:10.1016/j.ygyno.2017.12.00529233531
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Okamoto A, Enomoto T, et al. Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol. 2016;34(24):2881–2887. doi:10.1200/JCO.2016.66.901027400948
   PubMed Web of Science ®Google Scholar
• Schnack TH, Hogdall E, Nedergaard L, Hogdall C. Demographic clinical and prognostic factors of primary ovarian adenocarcinomas of serous and clear cell histology-a Comparative Study. Int J Gynecol Cancer. 2016;26(1):82–90. doi:10.1097/IGC.000000000000058526569060
   PubMed Web of Science ®Google Scholar
• Glasspool RM, McNeish IA. Clear cell carcinoma of ovary and uterus. Curr Oncol Rep. 2013;15(6):566–572. doi:10.1007/s11912-013-0346-024114188
   PubMed Web of Science ®Google Scholar
• Del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012;126(3):481–490. doi:10.1016/j.ygyno.2012.04.02122525820
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Shintani D, Nishikawa T. Clear-cell carcinoma of the ovary. Ann Oncol. 2016;27(Suppl 1):i50–i52. doi:10.1093/annonc/mdw08627141072
   PubMed Web of Science ®Google Scholar
• Oseledchyk A, Leitao MM Jr, Konner J, et al. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results Cohort Study, 2000–2013. Ann Oncol. 2017;28(12):2985–2993. doi:10.1093/annonc/mdx52528950307
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88(11):2584–2589. doi:10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-510861437
   PubMed Web of Science ®Google Scholar
• Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99(4):653–658. doi:10.1111/j.1349-7006.2008.00747.x18377417
   PubMed Web of Science ®Google Scholar
• Fang C, Zhang Y, Zhao L, Chen X, Xia L, Zhang P. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients. BMC Cancer. 2020;20(1):654. doi:10.1186/s12885-020-07144-132660444
   PubMed Web of Science ®Google Scholar
• Oncology FCoG. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014;125(2):97–98. doi:10.1016/j.ijgo.2014.02.00324630859
   PubMed Web of Science ®Google Scholar
• Machida H, Matsuo K, Yamagami W, et al. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol. 2019;153(3):589–596. doi:10.1016/j.ygyno.2019.03.24330905436
   PubMed Web of Science ®Google Scholar
• Suh DH, Kim JW, Kang S, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2013. J Gynecol Oncol. 2014;25(3):236–248. doi:10.3802/jgo.2014.25.3.23625045437
   PubMed Web of Science ®Google Scholar
• Takahashi K, Takenaka M, Kawabata A, Yanaihara N, Okamoto A. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. Int J Clin Oncol. 2020;25(3):425–431. doi:10.1007/s10147-020-01625-w31989349
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–1259. doi:10.1200/JCO.2002.20.5.124811870167
   PubMed Web of Science ®Google Scholar
• Sioulas VD, Schiavone MB, Kadouri D, et al. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol Oncol. 2017;145(1):15–20. doi:10.1016/j.ygyno.2017.02.02328238354
   PubMed Web of Science ®Google Scholar
• Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94(10):1369–1374. doi:10.1038/sj.bjc.660311616641903
   PubMed Web of Science ®Google Scholar
• Suidan RS, Zhou Q, Iasonos A, et al. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2015;25(4):599–606. doi:10.1097/IGC.000000000000038925664437
   PubMed Web of Science ®Google Scholar
• Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460–1466. doi:10.1200/JCO.2014.55.989825800756
   PubMed Web of Science ®Google Scholar
• Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273–282. doi:10.1038/nrc343223426401
   PubMed Web of Science ®Google Scholar
• Kim S, Kim B, Song YS. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016;107(9):1173–1178. doi:10.1111/cas.1298727297561
   PubMed Web of Science ®Google Scholar
• van Vliet MM, Schreuder HW, Pasker-de Jong PC, et al. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital. Eur J Obstet Gynecol Reprod Biol. 2015;192:72-78. doi:10.1016/j.ejogrb.2015.06.013
   Google Scholar
• Park JY, Kim DY, Suh DS, et al. Significance of ovarian endometriosis on the prognosis of ovarian clear cell carcinoma. Int J Gynecol Cancer. 2018;28(1):11–18. doi:10.1097/IGC.000000000000113628930811
   PubMed Web of Science ®Google Scholar
• Bertelsen K, Grenman S, Rustin GJ. How long should first-line chemotherapy continue? Ann Oncol. 1999;10(Suppl 1):17–20. doi:10.1016/S0923-7534(20)31479-410219448
   PubMed Web of Science ®Google Scholar
• Tozzi R, Giannice R, Cianci S, et al. Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol. 2015;138(2):252–258. doi:10.1016/j.ygyno.2015.05.01026003142
   PubMed Web of Science ®Google Scholar
• Chang SJ, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015;26(4):336–342. doi:10.3802/jgo.2015.26.4.33626197773
   PubMed Web of Science ®Google Scholar
• Oliver KE, Brady WE, Birrer M, et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017;147(2):243–249. doi:10.1016/j.ygyno.2017.08.00428807367
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT. Rethinking radical surgery in interval debulking surgery for advanced-stage ovarian cancer patients undergoing neoadjuvant chemotherapy. J Clin Med. 2020;9:4.
   Web of Science ®Google Scholar